PDCD1 and non-small cell lung carcinoma: In a retrospective study involving 406 NSCLC patients treated with PD-1/PD-L1 inhibitors, patients experiencing HPD within the first 6 weeks of treatment with PD-1/PD-L1 inhibitors had a significantly shorter overall survival (OS) than those with only progressive disease (median OS, 3.4 months versus 6.2 months; P = 0.003) (25).